A favorable article on GERN published to day said:
Wall Street Breakfast: Top Three Trending Stocks For The Day
Geron Corporation (NASDAQ:GERN) was a notable gainer on Tuesday, going up more than 16.60 percent. This followed a successful presentation by the company’s CEO John Scarlett at the 32nd Annual JPMorgan Healthcare conference. The presentation included plans to further development in myelofibrosis, imetelstat and its telomerase inhibitor. From the presentation, it was clear that the company’s management was executing well and that the company was fast moving towards solid financial position, positive free cash flow and strong balance sheet.
"From the presentation, it was clear that the company’s management was executing well and that the company was fast moving towards solid financial position, positive free cash flow and strong balance sheet."
Whether he is or he isn't, the statement makes no sense. Without engaging in substantial conjecture, positive free cash flow is nowhere in the picture for quite some time. Nor would one expect it to be for a company like Geron at Geron's stage of development.
I don't know if "Black" is reading this.....but many of us are becoming irritated and impatient with your, seemingly, never-ending penchant for "pumping" GERN stock by re-posting every positive statement that's ever been made concerning Geron Corporation.
I, too, am overjoyed over Geron's bright future, but I believe "pumping" drives more investors away than it attracts.
BY ADAM PARK
What lifted Geron Corporation (NASDAQ:GERN) shares?
Geron Corporation (NASDAQ:GERN) shares surged 19.42% Tuesday after CEO Dr. Scarlett, M.D., presented some additional updates on the Phase 2 trial of imetelstat at the JP Morgan Healthcare Conference. He laid out the plans for Imetelstat not only for MF which will begin a big Phase II study in the second half of this year, but also the potential plans for MDS and AML trials. Moreover, many investors believe when its drug hits the market there will be no direct competitors, enabling it to dominate this market.
Since the IDs, "end2war" and "mruyog" are just 2 of the many monikers used by the multiple ID, "fringe lunatic", Geron-negative, Bozo who's been spamming this board with its brain farts, lo, these many years, I refer readers to my reply to the post offered by "mruyog".